
Strides Pharma Global Pte. Ltd. has gained approval from the USFDA for a generic Mycophenolate Mofetil oral suspension, crucial for organ transplant patients to prevent rejection. This USFDA nod enhances Strides Pharma's Mycophenolate Mofetil portfolio, with the approved product being bioequivalent and therapeutically comparable to the reference-listed drug. The FDA approved the 200 mg/ml strength product set to be manufactured.
Like
Save
Share